Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa B ligand (RANKL). Denosumab has been shown to reduce the risk of skeletal-related events, including spinal cord compression, pathologic fracture and hypercalcemia of malignancy in patients with bone metastases. Hypocalcemia is a known side effect of denosumab, occurring in an estimated 8-14% of the patients. Here, we present an asymptomatic patient with stage-5 chronic kidney disease and severe hypocalcemia who had received denosumab 1 month earlier.
Keywords: Alkaline phosphatase; End-stage renal disease; Hypercalcemia of malignancy; Parathyroid hormone; RANKL inhibitor.
Copyright © 2017 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.